Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb and AbbVie Receive U.S. FDA Breakthrough Therapy Designation for Elotuzumab, an Investigational Humanized Monoclonal Antibody for Multiple Myeloma

[Business Wire] – Bristol-Myers Squibb Company and AbbVie today announced that the U.S. Food and Drug Administration has granted elotuzumab, an investigational humanized monoclonal antibody, Breakthrough Therapy Designation for use in combination with . . . → Read More: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb and AbbVie Receive U.S. FDA Breakthrough Therapy Designation for Elotuzumab, an Investigational Humanized Monoclonal Antibody for Multiple Myeloma Similar Articles: Market Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb Announces Retirement of Brian Daniels Company Update (NYSE:BMY): Bristol-Myers Squibb Ranks First on 2014 Best Corporate Citizens List Stock Update: Bristol-Myers Squibb Company (NYSE:BMY) – Bristol-Myers Squibb and Samsung BioLogics Expand Manufacturing Agreement